FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2211080015> ?p ?o ?g. }

• W2211080015 endingPage "2042" @default.
• W2211080015 startingPage "2031" @default.
• W2211080015 abstract "The ability of interferons (IFNs) to enhance tumor-associated antigen expression may be an important approach to enhance the efficacy of some monoclonal antibody (MAb)-based protocols for tumor diagnosis and/or therapy. The present study was designed to determine whether systemic IFN alpha-2a administration (via the intramuscular [IM] route) could upregulate the expression of tumor-associated glycoprotein-72 (TAG-72) and/or carcinoembryonic antigen (CEA) at histologically confirmed sites of carcinoma.Eighteen patients diagnosed with gastrointestinal (GI) carcinoma received systemic IFN alpha-2a according to four dose schedules. In cohorts I and II, patients received two injections of 3 or 6 x 10(6) U IFN alpha-2a per injection, respectively. Patients in cohorts III and IV received the same doses of IFN alpha-2a, 3 and 6 x 10(6) U, respectively, but three injections were given. Tumor and normal colonic mucosa biopsies were obtained from each patient by endoscopy before IFN alpha-2a and after IFN alpha-2a at surgery. The levels of TAG-72 and CEA expression were measured by (1) immunohistochemistry and reported as percent antigen-positive tumor cells, as well as the relative staining intensity, and (2) a quantitative radioimmunoassay.TAG-72 and CEA levels were consistently increased in tumor biopsies taken from patients in cohorts III and IV. For example, of 10 patients treated in cohorts III and IV, eight had enhanced TAG-72 expression when measured either as percentage TAG-72-positive tumor cells or as an increased MAb staining intensity following IFN alpha-2a. CEA expression in tumor biopsies from seven of 10 patients in cohorts III and IV was also elevated following IFN alpha-2a treatment. Quantitative analysis of TAG-72 and CEA levels in tumor biopsies confirmed higher tumor antigen levels following IFN alpha-2a administration. No such increases in TAG-72 or CEA levels were observed in tumor samples taken from patients in cohorts I and II. CEA or TAG-72 expression in samples of histologically confirmed normal colonic mucosa showed little or no change after IFN alpha-2a treatment.Systemic IFN alpha-2a administration can upregulate TAG-72 and CEA expression at distal tumor sites, which may play an important role in immunodiagnosis and therapy." @default.
• W2211080015 created "2016-06-24" @default.
• W2211080015 creator A5012648072 @default.
• W2211080015 creator A5051393909 @default.
• W2211080015 creator A5054281668 @default.
• W2211080015 creator A5059931764 @default.
• W2211080015 creator A5062002707 @default.
• W2211080015 creator A5068002072 @default.
• W2211080015 creator A5072842070 @default.
• W2211080015 creator A5083069534 @default.
• W2211080015 creator A5087184743 @default.
• W2211080015 date "1996-07-01" @default.
• W2211080015 modified "2023-09-23" @default.
• W2211080015 title "Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen." @default.
• W2211080015 cites W123319480 @default.
• W2211080015 cites W1572314647 @default.
• W2211080015 cites W1601111541 @default.
• W2211080015 cites W1604623448 @default.
• W2211080015 cites W1607870128 @default.
• W2211080015 cites W1654548623 @default.
• W2211080015 cites W1807942412 @default.
• W2211080015 cites W1869542520 @default.
• W2211080015 cites W1990246315 @default.
• W2211080015 cites W2004102690 @default.
• W2211080015 cites W2015137936 @default.
• W2211080015 cites W2023177577 @default.
• W2211080015 cites W2031928907 @default.
• W2211080015 cites W2042178436 @default.
• W2211080015 cites W2048567466 @default.
• W2211080015 cites W2073090456 @default.
• W2211080015 cites W2078423573 @default.
• W2211080015 cites W2081543802 @default.
• W2211080015 cites W2083794542 @default.
• W2211080015 cites W2086940701 @default.
• W2211080015 cites W2087833524 @default.
• W2211080015 cites W2096428903 @default.
• W2211080015 cites W2107619042 @default.
• W2211080015 cites W2118641357 @default.
• W2211080015 cites W2121988246 @default.
• W2211080015 cites W2143372682 @default.
• W2211080015 cites W2150612230 @default.
• W2211080015 cites W2151010275 @default.
• W2211080015 cites W2155854805 @default.
• W2211080015 cites W2338107399 @default.
• W2211080015 cites W2418207395 @default.
• W2211080015 cites W2441192832 @default.
• W2211080015 cites W78884675 @default.
• W2211080015 cites W1581503953 @default.
• W2211080015 doi "https://doi.org/10.1200/jco.1996.14.7.2031" @default.
• W2211080015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8683233" @default.
• W2211080015 hasPublicationYear "1996" @default.
• W2211080015 type Work @default.
• W2211080015 sameAs 2211080015 @default.
• W2211080015 citedByCount "35" @default.
• W2211080015 countsByYear W22110800152012 @default.
• W2211080015 countsByYear W22110800152013 @default.
• W2211080015 countsByYear W22110800152020 @default.
• W2211080015 crossrefType "journal-article" @default.
• W2211080015 hasAuthorship W2211080015A5012648072 @default.
• W2211080015 hasAuthorship W2211080015A5051393909 @default.
• W2211080015 hasAuthorship W2211080015A5054281668 @default.
• W2211080015 hasAuthorship W2211080015A5059931764 @default.
• W2211080015 hasAuthorship W2211080015A5062002707 @default.
• W2211080015 hasAuthorship W2211080015A5068002072 @default.
• W2211080015 hasAuthorship W2211080015A5072842070 @default.
• W2211080015 hasAuthorship W2211080015A5083069534 @default.
• W2211080015 hasAuthorship W2211080015A5087184743 @default.
• W2211080015 hasConcept C121608353 @default.
• W2211080015 hasConcept C126322002 @default.
• W2211080015 hasConcept C142724271 @default.
• W2211080015 hasConcept C147483822 @default.
• W2211080015 hasConcept C159654299 @default.
• W2211080015 hasConcept C203014093 @default.
• W2211080015 hasConcept C204232928 @default.
• W2211080015 hasConcept C2776178377 @default.
• W2211080015 hasConcept C2776869981 @default.
• W2211080015 hasConcept C2777387746 @default.
• W2211080015 hasConcept C2777546739 @default.
• W2211080015 hasConcept C2781228144 @default.
• W2211080015 hasConcept C2909179924 @default.
• W2211080015 hasConcept C3019217517 @default.
• W2211080015 hasConcept C542903549 @default.
• W2211080015 hasConcept C71924100 @default.
• W2211080015 hasConcept C90924648 @default.
• W2211080015 hasConceptScore W2211080015C121608353 @default.
• W2211080015 hasConceptScore W2211080015C126322002 @default.
• W2211080015 hasConceptScore W2211080015C142724271 @default.
• W2211080015 hasConceptScore W2211080015C147483822 @default.
• W2211080015 hasConceptScore W2211080015C159654299 @default.
• W2211080015 hasConceptScore W2211080015C203014093 @default.
• W2211080015 hasConceptScore W2211080015C204232928 @default.
• W2211080015 hasConceptScore W2211080015C2776178377 @default.
• W2211080015 hasConceptScore W2211080015C2776869981 @default.
• W2211080015 hasConceptScore W2211080015C2777387746 @default.
• W2211080015 hasConceptScore W2211080015C2777546739 @default.
• W2211080015 hasConceptScore W2211080015C2781228144 @default.
• W2211080015 hasConceptScore W2211080015C2909179924 @default.
• W2211080015 hasConceptScore W2211080015C3019217517 @default.

• next